General Considerations for Clinical Studies
The foundational ICH efficacy guideline describing the general principles for the design and conduct of clinical studies across a drug development programme. The R1 revision introduces "quality by design" and the concept of identifying factors critical to the quality of a study early, aligning E8 with the risk-proportionate philosophy later embedded in E6(R3).
What this does not cover
stated in the document's own scope- Sets general design principles across a development programme, not the operational GCP for conducting a trial, which is ICH E6(R3).
- Covers study design considerations, not the statistical principles for analysis, which are ICH E9.
- Provides a conceptual framework, not binding procedural requirements — those live in the region’s clinical-trial law.
- Addresses clinical (human) studies, not nonclinical safety studies, which follow Good Laboratory Practice.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
ICH E8(R1) is the foundational ICH Efficacy guideline describing the general principles for the design and conduct of clinical studies across a drug-development programme. It provides the framework within which the more detailed efficacy and GCP guidelines operate: types of studies, the elements of study design, and the considerations that run through a development plan. The R1 revision introduced the concept of Quality by Design for clinical studies and the identification of factors critical to the quality of a study early in its design — so that quality is built into the study from the protocol onward rather than inspected in afterwards, aligning E8 with the risk-proportionate philosophy later embedded in E6(R3).
Scope & applicability
Applies across the clinical development lifecycle for investigational medicinal products in ICH regions; a companion framework to E6 GCP and the E9 statistical principles.
Legal basis & how it acquires force
E8 is an ICH Efficacy guideline; the R1 revision reached Step 4 on 6 October 2021. An ICH guideline is not itself law; regions implement it. The FDA issued E8(R1) as a guidance for industry, the EMA adopted it as a scientific guideline, and Japan gives it effect through MHLW. E8 sets general principles rather than binding procedural requirements, so it is applied as the conceptual foundation beneath the region’s GCP and clinical-trial law rather than as an enforceable rule in its own right.
Document structure
| Part | Covers |
|---|---|
| General principles | Protection of participants and the scientific principles underlying clinical studies |
| Designing quality into studies | Quality by Design and the identification of factors critical to quality (CtQ) |
| Types of clinical studies | Study types across the development programme and their objectives |
| Elements of study design | Study population, control, endpoints, and other design considerations |
| The development plan | How individual studies fit into an overall drug-development programme |
| Critical-to-quality factors (Annex) | Illustrative critical-to-quality factors and how to identify and prioritise them |
Key requirements
- Identify factors critical to quality proactively during study design
- Adopt a proportionate, fit-for-purpose approach to study conduct and oversight
- Engage relevant stakeholders, including patients, in study design where appropriate
Implementation tips
- Run a documented CtQ workshop at protocol concept stage and carry outputs into the monitoring plan
- Use E8(R1) as the bridge document when training teams on the E6(R3) quality-by-design shift
Revision notes
R1 revision adopted 6 October 2021, adding quality-by-design and critical-to-quality-factor concepts to the original E8 (1997).
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
E8(R1) is the entry point to the ICH Efficacy series and the conceptual parent of E6(R3): E8 frames the general principles and the critical-to-quality thinking, and E6 implements them as operational GCP. It connects to the disease- and endpoint-specific E-series guidelines and to the statistical guidance E9, and its quality-by-design language mirrors the risk-management approach of the ICH quality guidelines.
ICH E8(R1): frequently asked questions
Quick answers to common questions about ICH E8(R1).
What did the R1 revision add to ICH E8?
R1, finalised on 6 October 2021, introduced Quality by Design for clinical studies and the concept of identifying factors critical to the quality of a study early in its design — building quality in from the start and aligning E8 with the risk-proportionate approach of E6(R3).
How does ICH E8 relate to ICH E6?
E8(R1) sets the general principles and the critical-to-quality framing for clinical studies; E6(R3) turns those principles into operational Good Clinical Practice. E8 is the conceptual foundation and E6 is the detailed conduct standard.
What are critical-to-quality factors in ICH E8(R1)?
They are the attributes of a study whose integrity is essential to the reliability of its results and the protection of participants. E8(R1) asks sponsors to identify and prioritise these factors early so quality-management effort is focused where it matters most.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.